ImmunoCellular Therapeutics Ltd  

(Public, NYSEMKT:IMUC)   Watch this stock  
Find more results for imuc
0.230
-0.003 (-1.20%)
Jun 30 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.22 - 0.24
52 week 0.20 - 0.63
Open 0.23
Vol / Avg. 373,037.00/352,783.00
Mkt cap 21.05M
P/E     -
Div/yield     -
EPS -0.19
Shares 93.22M
Beta 0.67
Inst. own 13%
Aug 4, 2016
Q2 2016 ImmunoCellular Therapeutics Ltd Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 24, 2016
ImmunoCellular Therapeutics Ltd Annual Shareholders Meeting (Estimated)
Jun 17, 2016
ImmunoCellular Therapeutics Ltd Annual Shareholders Meeting
Jun 2, 2016
ImmunoCellular Therapeutics Ltd at Marcum MicroCap Conference
May 12, 2016
Q1 2016 ImmunoCellular Therapeutics Ltd Earnings Call
May 12, 2016
Q1 2016 ImmunoCellular Therapeutics Ltd Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -82.50% -46.29%
Return on average equity -118.14% -56.83%
Employees 6 -
CDP Score - -

Address

23622 Calabasas Rd Ste 300
CALABASAS, CA 91302-1672
United States - Map
+1-818-2642300 (Phone)
+1-818-2245287 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.

Officers and directors

Andrew Gengos President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Anthony J. Gringeri Ph.D. Senior Vice President - Strategic Resources
Age: 62
Bio & Compensation  - Reuters
David E. Fractor Principal Accounting Officer, Vice President - Finance
Age: 55
Bio & Compensation  - Reuters
Rahul Singhvi Lead Independent Director
Age: 50
Bio & Compensation  - Reuters
John S. Yu M.D. Director
Age: 51
Bio & Compensation  - Reuters
Gregg A. Lapointe CPA Independent Director
Age: 56
Bio & Compensation  - Reuters
Mark A. Schlossberg Esq. Independent Director
Age: 54
Bio & Compensation  - Reuters
Gary S. Titus Independent Director
Age: 55
Bio & Compensation  - Reuters